On February 24, 2021, Vividion Therapeutics, Inc., a biotechnology company focused on developing highly selective small molecule medicines that drug traditionally inaccessible targets, announced the completion of a $135 million Series C financing. The financing was co-led by new investors Logos Capital and Boxer Capital of Tavistock Group. Wilson Sonsini Goodrich & Rosati advised the lead investors on the financing.

Vividion’s “’unique platform technologies’” enable the company to discover and develop potential therapies for well-known but previously undruggable targets. Leveraging this platform, Vividion is advancing a pipeline of potent and selective small molecule therapies across a range of oncology and immunology programs.

The Wilson Sonsini team advising Logos Capital and Boxer Capital includes partner Dan Koeppen, associate Meghan Burton, and venture counsel attorneys Bridget Balisy and Brandon Shaw.

Please see the Vividion’s press release for more information.